MiniMed Group (NASDAQ:MMED) Coverage Initiated by Analysts at Benchmark

Stock analysts at Benchmark began coverage on shares of MiniMed Group (NASDAQ:MMED) in a report released on Tuesday,Benzinga reports. The brokerage set a “buy” rating and a $20.00 price target on the stock. Benchmark’s price target suggests a potential upside of 79.21% from the stock’s current price.

Other equities research analysts have also recently issued research reports about the company. Wells Fargo & Company started coverage on MiniMed Group in a research note on Tuesday, March 31st. They issued an “overweight” rating and a $26.00 price target for the company. Wall Street Zen upgraded MiniMed Group to a “hold” rating in a report on Saturday, March 14th. Morgan Stanley initiated coverage on MiniMed Group in a report on Tuesday, March 31st. They set an “overweight” rating and a $19.00 price target on the stock. Barclays initiated coverage on MiniMed Group in a report on Wednesday, April 1st. They set an “overweight” rating and a $26.00 price target on the stock. Finally, William Blair initiated coverage on MiniMed Group in a report on Tuesday, March 31st. They set an “outperform” rating on the stock. Twelve research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $22.25.

MiniMed Group Price Performance

Shares of NASDAQ MMED opened at $11.16 on Tuesday. The firm has a 50 day moving average price of $14.48. MiniMed Group has a 52 week low of $11.10 and a 52 week high of $20.48.

About MiniMed Group

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.